Pulse Biosciences (NASDAQ: PLSE) sets up $75M at-the-market stock program
Rhea-AI Filing Summary
Pulse Biosciences, Inc. entered into an equity distribution agreement with Mizuho Securities USA LLC as sales agent, under which the company may, from time to time, offer and sell shares of its common stock having an aggregate offering price of up to $75,000,000.
Sales may be made as “at the market” offerings under Rule 415 through ordinary brokers’ transactions on The Nasdaq Capital Market, to or through market makers, block trades, or other permitted negotiated methods, at market, related, or negotiated prices. The company will pay Mizuho a commission of up to 3.0% of the gross sales price of shares sold, reimburse specified expenses, is not obligated to sell any shares, and may suspend solicitations. The shares are registered on Form S-3 (File No. 333-293596), declared effective February 27, 2026, with a prospectus supplement filed August 6, 2026.
Positive
- None.
Negative
- None.
Filing Explained
The August 6 8-K records an at-the-market program authorizing up to
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
ATM capacity: $75,000,000
Sales agent commission: 3.0%
Registration statement file number: 333-293596
+2 more
5 metrics
ATM capacity
$75,000,000
Aggregate offering price of common stock that may be sold under the equity distribution agreement
Sales agent commission
3.0%
Maximum commission rate on the gross sales price of shares sold through Mizuho
Registration statement file number
333-293596
Form S-3 registration statement covering the shares sold under the program
Form S-3 effectiveness date
February 27, 2026
Date the Form S-3 registration statement was declared effective
Prospectus supplement filing date
August 6, 2026
Date the prospectus supplement was filed for the at-the-market offering
Key Terms
equity distribution agreement, at the market offerings, Rule 415, registration statement on Form S-3, +1 more
5 terms
equity distribution agreement financial
"entered into an equity distribution agreement (the “Sales Agreement”) with Mizuho"
An equity distribution agreement is a formal plan between a company and financial institutions to sell newly issued shares of the company's stock to investors over a period of time. It helps the company raise money gradually, similar to filling a container with water in stages, rather than all at once. For investors, it provides an organized way to buy shares and can influence the stock's supply and price.
at the market offerings financial
"may sell Shares in transactions that are deemed to be “at the market” offerings"
At-the-market offerings are a way for a company to raise cash by selling newly issued shares directly into the open market at the current trading price through a broker, rather than in a single large sale. Think of it like topping up a gas tank a little at a time at whatever the pump price is; it gives the company flexibility to raise money when conditions are favorable but can increase the number of shares outstanding and dilute existing investors, and frequent or large sales can put downward pressure on the stock price.
Rule 415 regulatory
"“at the market” offerings as defined in Rule 415 under the Securities Act"
Rule 415 is a U.S. Securities and Exchange Commission regulation that lets a company register securities ahead of time and then offer them for sale in pieces over an extended period under a “shelf” registration, so offerings can be launched quickly when market conditions suit the issuer. For investors, it signals that management has a ready way to raise capital fast—useful for seizing opportunities but potentially dilutive to existing shareholders, like a company pre-loading a credit line it can tap as needed.
registration statement on Form S-3 regulatory
"pursuant to the Company’s effective registration statement on Form S-3"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
prospectus supplement regulatory
"The Company filed a prospectus supplement with the SEC on August 6, 2026"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Pulse Biosciences (PLSE) announce regarding its common stock sales?
Pulse Biosciences entered into an equity distribution agreement with Mizuho Securities USA LLC, allowing it to offer and sell, from time to time, up to $75,000,000 of its common stock through at-the-market and other permitted transactions.
How much stock can Pulse Biosciences (PLSE) sell under the Mizuho agreement?
Pulse Biosciences may sell shares of common stock having an aggregate offering price of up to $75,000,000. These shares can be issued over time through Mizuho Securities USA LLC acting as sales agent in various at-the-market or negotiated transactions.
What commission will Pulse Biosciences (PLSE) pay Mizuho for stock sales?
Pulse Biosciences will pay Mizuho Securities USA LLC a commission of up to 3.0% of the gross sales price of any shares sold. The company will also reimburse Mizuho for certain specified expenses related to entering into the equity distribution agreement.